医学
内科学
化疗
淋巴母细胞淋巴瘤
淋巴瘤
胃肠病学
骨髓
存活率
外科
肿瘤科
免疫系统
T细胞
免疫学
作者
Ping Yang,Wei Zhao,Hongmei Jing,Kai Hu,Wei Wan,Jijun Wang,Xiaoyan Ke
出处
期刊:PubMed
日期:2016-08-01
卷期号:24 (4): 1056-60
被引量:1
标识
DOI:10.7534/j.issn.1009-2137.2016.04.018
摘要
T-LBL is more common in young men, with large mediastinal mass and bone marrow involvement. ALL-like chemotherapy regimens are superior to NHL-like regimens, HSCT can improve the survival and reduce the recurrence of adult patients. Chemotherapy combined with allogeneic DC/CIK immune cell treatment can be used in relapsed patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI